ML385: Selective NRF2 Inhibitor for Cancer and Oxidative Stress Research

Executive Summary: ML385 (CAS 846557-71-9) is a potent and selective inhibitor of the transcription factor NRF2, with an IC₅₀ of 1.9 μM in biochemical assays (APExBIO). ML385 downregulates NRF2-dependent gene expression in a dose- and time-dependent manner, particularly in A549 non-small cell lung cancer (NSCLC) cells (Wang et al., 2024). In vivo, ML385 reduces tumor growth and metastasis, especially when combined with standard chemotherapeutics such as carboplatin (related review). ML385 is also used to dissect oxidative stress, ferroptosis, and inflammation pathways. The compound is supplied by APExBIO for research use only and is not intended for diagnostic or therapeutic applications.

Biological Rationale

NRF2 is a transcription factor that regulates genes responsible for cellular antioxidant responses, detoxification, and multidrug transporter expression (Wang et al., 2024). Overactivation of NRF2 contributes to therapeutic resistance in various cancers, including NSCLC. NRF2-driven pathways modulate oxidative stress by controlling the expression of heme oxygenase-1 (HO-1), glutathione peroxidase 4 (GPX4), and glutathione synthesis enzymes. Inhibiting NRF2 allows researchers to evaluate the impact of suppressed antioxidant response on disease progression, resistance mechanisms, and cell death modalities such as ferroptosis (see advanced analysis). ML385, as a selective NRF2 pathway inhibitor, enables controlled interrogation of these responses in cellular and animal models.

Mechanism of Action of ML385

ML385 binds directly to the Neh1 DNA-binding domain of NRF2, preventing its interaction with antioxidant response elements (ARE) on target gene promoters (APExBIO). This inhibition blocks the transcriptional activation of NRF2-dependent genes, resulting in reduced expression of proteins such as HO-1, GPX4, and multidrug transporters. The effect is dose-dependent, with maximal inhibition observed at concentrations ≥5 μM in vitro. ML385 is chemically described as 2-(benzo[d][1,3]dioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)indolin-5-yl)thiazol-2-yl)acetamide (MW 511.59, C₂₉H₂₅N₃O₄S). It is insoluble in water and ethanol, but soluble at ≥13.33 mg/mL in DMSO, and should be stored at –20°C for optimal stability (source).

Evidence & Benchmarks

• ML385 inhibits NRF2 transcriptional activity with an IC₅₀ of 1.9 μM in cell-based assays (APExBIO).
• ML385 blocks upregulation of NRF2 target genes (HO-1, GPX4, GCLC) in A549 NSCLC cells in a dose- and time-dependent manner (Wang et al., 2024).
• In NSCLC mouse models, ML385 alone reduces tumor volume and metastatic burden; effects are potentiated in combination with carboplatin chemotherapy (review).
• ML385 abolishes neuroprotective effects of artemisinin in T2DM mice, confirming its efficacy as an NRF2 inhibitor in vivo (Wang et al., 2024).
• ML385 is widely used to induce oxidative stress and ferroptosis in research models by inhibiting NRF2-dependent antioxidant pathways (mechanistic summary).

Applications, Limits & Misconceptions

ML385 is primarily used in cancer biology to evaluate NRF2-dependent therapeutic resistance and in studies of oxidative stress, ferroptosis, and inflammation. Its application includes:

• Investigation of NRF2 signaling in NSCLC and other cancers.
• Modulation of antioxidant response pathways in metabolic and neurodegenerative disease models.
• Combination therapy studies, e.g., ML385 with carboplatin to overcome chemoresistance (see strategic review).
• Probing the role of NRF2 in ferroptosis and cell death mechanisms.

Common Pitfalls or Misconceptions

• ML385 is not suitable for diagnostic or therapeutic use in humans; it is for research only (APExBIO).
• It is not effective in models where NRF2 is not the primary driver of antioxidant response or resistance.
• ML385 does not chelate iron or act as a direct antioxidant; its effects are mediated exclusively through NRF2 inhibition.
• Long-term storage of ML385 solutions in DMSO is discouraged due to degradation; solid or frozen aliquots are recommended.
• Solubility limitations exist in aqueous buffers; DMSO is required for stock preparation.

Workflow Integration & Parameters

For experimental use, ML385 is typically dissolved in DMSO to create a ≥13.33 mg/mL stock solution. Working concentrations range from 1–10 μM in cell culture; lower concentrations may be used for in vivo studies, depending on model and route of administration. ML385 is best stored at –20°C as a solid or frozen aliquot; avoid repeated freeze-thaw cycles. Researchers should validate NRF2 pathway inhibition using downstream target gene expression (e.g., HO-1, GPX4) as readouts. For combination therapy studies, ML385 can be co-administered with carboplatin or other chemotherapeutics to evaluate synergistic effects on tumor growth and resistance (detailed protocol guide – this article offers updated evidence and storage guidance).

Conclusion & Outlook

ML385 is a validated, selective NRF2 pathway inhibitor with wide utility in cancer and oxidative stress research. Its ability to downregulate NRF2-dependent gene expression and overcome therapeutic resistance in NSCLC, especially in combination with chemotherapeutics, is well-supported by in vitro and in vivo data. ML385 also serves as a tool for dissecting ferroptosis and inflammation pathways. As a research reagent supplied by APExBIO, ML385 continues to enable advances in understanding redox biology, multidrug resistance, and cell death mechanisms. For the latest data and protocols, refer to the ML385 product page and recent peer-reviewed literature.